BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang YF, Dai YH, Lin CS, Chang HC, Shen PC, Yang JF, Hsiang CW, Lo CH, Huang WY. Clinical outcome and pathologic correlation of stereotactic body radiation therapy as a bridge to transplantation for advanced hepatocellular carcinoma: a case series. Radiat Oncol 2021;16:15. [PMID: 33446231 DOI: 10.1186/s13014-020-01739-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int 2021. [PMID: 34515412 DOI: 10.1111/liv.15052] [Reference Citation Analysis]
2 Bauer U, Gerum S, Roeder F, Münch S, Combs SE, Philipp AB, De Toni EN, Kirstein MM, Vogel A, Mogler C, Haller B, Neumann J, Braren RF, Makowski MR, Paprottka P, Guba M, Geisler F, Schmid RM, Umgelter A, Ehmer U. High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy. World J Gastroenterol 2021; 27(24): 3630-3642 [PMID: 34239274 DOI: 10.3748/wjg.v27.i24.3630] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gu YF, Kong LT. Inhibiting p21-activated kinase (PAK7) enhances radiosensitivity in hepatocellular carcinoma. Hum Exp Toxicol 2021;:9603271211027948. [PMID: 34165002 DOI: 10.1177/09603271211027948] [Reference Citation Analysis]